Literature DB >> 7758874

Excessive glucose production, rather than insulin resistance, accounts for hyperglycaemia in recent-onset streptozotocin-diabetic rats.

R Burcelin1, M Eddouks, J Maury, J Kande, R Assan, J Girard.   

Abstract

Glucose production and utilization and activities of key enzymes involved in liver and muscle glucose metabolism were studied in post-absorptive streptozotocin-diabetic rats after 12 h of severe hyperglycaemia (17.5 +/- 0.5 mmol/l) and insulinopenia (5 +/- 1 microU/ml). Basal glucose production was increased: 36.6 +/- 3.0 mg.kg.min-1, vs 24.4 +/- 2.5 in controls (p < 0.05); liver glycogen concentration was decreased by 40% (p < 0.05); liver phosphoenolpyruvate carboxykinase and glucose-6-phosphatase activities were increased by 375 and 156%, respectively (p < 0.001 and < 0.01). During a euglycaemic clamp at a plasma insulin level of 200 microU/ml, glucose production was totally suppressed in controls, but persisted at 20% of basal in diabetic rats. In these rats, glucose production was suppressed at a plasma insulin level of 2500 microU/ml. Basal whole body glucose utilization rate, 2-deoxy-1-[3H]-D-glucose ([3H]-2DG) uptake by muscles and muscle glycogen concentrations were similar in both groups, as well as total and active forms of pyruvate dehydrogenase and glycogen synthase activities. During the euglycaemic clamp, the total body glucose utilization rates and [3H]-2DG uptake by muscles were similar in control and diabetic rats at a plasma insulin level of 200 microU/ml, but lower in diabetic rats at a plasma insulin level of 2500 microU/ml. We conclude 1) in recent-onset severely insulinopenic rats, an excessive glucose production via gluconeogenesis prevailed, mainly accounting for the concomitant hyperglycaemia. This excess glucose output cannot be attributed to liver insulin resistance: the gluconeogenic pathway is physiologically less sensitive than glycogenolysis to the inhibition by insulin.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7758874     DOI: 10.1007/BF00400632

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  42 in total

1.  Whole body and hepatic insulin action in normal, starved, and diabetic rats.

Authors:  S J Koopmans; S F de Boer; H C Sips; J K Radder; M Frölich; H M Krans
Journal:  Am J Physiol       Date:  1991-06

2.  Studies on gluconeogenesis and ketogenesis in isolated hepatocytes from alloxan diabetic rats.

Authors:  S R Wagle; W R Ingebretsen
Journal:  Proc Soc Exp Biol Med       Date:  1975-12

3.  Relative contribution of glycogen synthesis and glycolysis to insulin-mediated glucose uptake. A dose-response euglycemic clamp study in normal and diabetic rats.

Authors:  L Rossetti; A Giaccari
Journal:  J Clin Invest       Date:  1990-06       Impact factor: 14.808

4.  Hepatic and peripheral insulin resistance following streptozotocin-induced insulin deficiency in the dog.

Authors:  S Bevilacqua; E J Barrett; D Smith; D C Simonson; M Olsson; P Bratusch-Marrain; E Ferrannini; R A DeFronzo
Journal:  Metabolism       Date:  1985-09       Impact factor: 8.694

5.  Glucose and free fatty acid turnover in normal subjects and in diabetic patients before and after insulin treatment.

Authors:  S E Hall; J Saunders; P H Sönksen
Journal:  Diabetologia       Date:  1979-05       Impact factor: 10.122

6.  Relationship of skeletal muscle glucose 6-phosphate to glucose disposal rate and glycogen synthase activity in insulin-resistant and non-insulin-dependent diabetic rhesus monkeys.

Authors:  H K Ortmeyer; N L Bodkin; B C Hansen
Journal:  Diabetologia       Date:  1994-02       Impact factor: 10.122

7.  Effects of insulin perfusion and altered glucose concentrations on heart function in 3-day and 6-week diabetic rats.

Authors:  A G Tahiliani; J H McNeill
Journal:  Can J Physiol Pharmacol       Date:  1986-02       Impact factor: 2.273

8.  Hypoglycemic effects of a beta-agonist, Ro 16-8714, in streptozotocin-diabetic rats: decreased hepatic glucose production and increased glucose utilization in oxidative muscles.

Authors:  P Ferré; L Pénicaud; Y Hitier; M Meier; J Girard
Journal:  Metabolism       Date:  1992-02       Impact factor: 8.694

9.  Evidence that GLUT-2 mRNA and protein concentrations are decreased by hyperinsulinaemia and increased by hyperglycaemia in liver of diabetic rats.

Authors:  R Burcelin; M Eddouks; J Kande; R Assan; J Girard
Journal:  Biochem J       Date:  1992-12-01       Impact factor: 3.857

10.  Regulation of pyruvate dehydrogenase in rat heart. Mechanism of regulation of proportions of dephosphorylated and phosphorylated enzyme by oxidation of fatty acids and ketone bodies and of effects of diabetes: role of coenzyme A, acetyl-coenzyme A and reduced and oxidized nicotinamide-adenine dinucleotide.

Authors:  A L Kerbey; P J Randle; R H Cooper; S Whitehouse; H T Pask; R M Denton
Journal:  Biochem J       Date:  1976-02-15       Impact factor: 3.857

View more
  17 in total

1.  Antihyperglycemic effects of Platycodon grandiflorum (Jacq.) A. DC. extract on streptozotocin-induced diabetic mice.

Authors:  Jie Zheng; Jiguo He; Baoping Ji; Ye Li; Xiaofeng Zhang
Journal:  Plant Foods Hum Nutr       Date:  2007-01-17       Impact factor: 3.921

2.  Glucose intolerance modifies the inflammatory response after intestinal ischemia-reperfusion.

Authors:  Juan C Garcia-Perez; Javier Arias-Diaz; Elena Vara; Jose L Balibrea
Journal:  World J Surg       Date:  2005-09       Impact factor: 3.352

3.  Hyperglucagonemia precedes a decline in insulin secretion and causes hyperglycemia in chronically glucose-infused rats.

Authors:  Rachel A Jamison; Romana Stark; Jianying Dong; Shin Yonemitsu; Dongyan Zhang; Gerald I Shulman; Richard G Kibbey
Journal:  Am J Physiol Endocrinol Metab       Date:  2011-08-23       Impact factor: 4.310

4.  Pancreatic islet regeneration and some liver biochemical parameters of leaf extracts of Vitex doniana in normal and streptozotocin-induced diabetic albino rats.

Authors:  Okpe Oche; Ibrahim Sani; Njoku Godwin Chilaka; Ndidi Uche Samuel; Atabo Samuel
Journal:  Asian Pac J Trop Biomed       Date:  2014-02

5.  Hepatic glucose sensing is required to preserve β cell glucose competence.

Authors:  Pascal Seyer; David Vallois; Carole Poitry-Yamate; Frédéric Schütz; Salima Metref; David Tarussio; Pierre Maechler; Bart Staels; Bernard Lanz; Rolf Grueter; Julie Decaris; Scott Turner; Anabela da Costa; Frédéric Preitner; Kaori Minehira; Marc Foretz; Bernard Thorens
Journal:  J Clin Invest       Date:  2013-03-15       Impact factor: 14.808

6.  The AMP-activated protein kinase alpha2 catalytic subunit controls whole-body insulin sensitivity.

Authors:  Benoit Viollet; Fabrizio Andreelli; Sebastian B Jørgensen; Christophe Perrin; Alain Geloen; Daisy Flamez; James Mu; Claudia Lenzner; Olivier Baud; Myriam Bennoun; Emmanuel Gomas; Gaël Nicolas; Jørgen F P Wojtaszewski; Axel Kahn; David Carling; Frans C Schuit; Morris J Birnbaum; Erik A Richter; Rémy Burcelin; Sophie Vaulont
Journal:  J Clin Invest       Date:  2003-01       Impact factor: 14.808

7.  Blocking VLDL secretion causes hepatic steatosis but does not affect peripheral lipid stores or insulin sensitivity in mice.

Authors:  Kaori Minehira; Stephen G Young; Claudio J Villanueva; Laxman Yetukuri; Matej Oresic; Mark K Hellerstein; Robert V Farese; Jay D Horton; Frederic Preitner; Bernard Thorens; Luc Tappy
Journal:  J Lipid Res       Date:  2008-06-01       Impact factor: 5.922

8.  Evaluation of anti-diabetic potential of leaves and stem of Flacourtia jangomas in streptozotocin-induced diabetic rats.

Authors:  Ajay Kumar Singh; Jyoti Singh
Journal:  Indian J Pharmacol       Date:  2010-10       Impact factor: 1.200

Review 9.  Therapeutic potentials of agonist and antagonist of adenosine receptors in type 2 diabetes.

Authors:  Olakunle Sanni; G Terre'Blanche
Journal:  Rev Endocr Metab Disord       Date:  2021-06-24       Impact factor: 6.514

10.  Antihyperglycemic and antihyperlipidemic activities of aqueous extract of Hericium erinaceus in experimental diabetic rats.

Authors:  Bin Liang; Zhengdong Guo; Fang Xie; Ainong Zhao
Journal:  BMC Complement Altern Med       Date:  2013-10-03       Impact factor: 3.659

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.